- Home
- GDYN vs ARQT Comparison
GDYN vs ARQT Comparison
Compare GDYN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDYN
- ARQT
- Stock Information
- Founded
- GDYN 2006
- ARQT 2016
- Country
- GDYN United States
- ARQT United States
- Employees
- GDYN N/A
- ARQT N/A
- Industry
- GDYN Computer Software: Prepackaged Software
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- GDYN Technology
- ARQT Health Care
- Exchange
- GDYN Nasdaq
- ARQT Nasdaq
- Market Cap
- GDYN 1.1B
- ARQT 1.1B
- IPO Year
- GDYN N/A
- ARQT 2020
- Fundamental
- Price
- GDYN $14.02
- ARQT $10.53
- Analyst Decision
- GDYN Strong Buy
- ARQT Buy
- Analyst Count
- GDYN 6
- ARQT 6
- Target Price
- GDYN $15.83
- ARQT $14.40
- AVG Volume (30 Days)
- GDYN 316.5K
- ARQT 1.9M
- Earning Date
- GDYN 10-31-2024
- ARQT 11-01-2024
- Dividend Yield
- GDYN N/A
- ARQT N/A
- EPS Growth
- GDYN N/A
- ARQT N/A
- EPS
- GDYN N/A
- ARQT N/A
- Revenue
- GDYN $318,342,000.00
- ARQT $132,062,000.00
- Revenue This Year
- GDYN $8.61
- ARQT $185.11
- Revenue Next Year
- GDYN $14.12
- ARQT $48.43
- P/E Ratio
- GDYN N/A
- ARQT N/A
- Revenue Growth
- GDYN N/A
- ARQT 1032.90
- 52 Week Low
- GDYN $9.07
- ARQT $1.76
- 52 Week High
- GDYN $14.70
- ARQT $13.17
- Technical
- Relative Strength Index (RSI)
- GDYN 56.66
- ARQT 56.39
- Support Level
- GDYN $13.97
- ARQT $10.09
- Resistance Level
- GDYN $14.67
- ARQT $10.95
- Average True Range (ATR)
- GDYN 0.49
- ARQT 0.64
- MACD
- GDYN -0.03
- ARQT 0.02
- Stochastic Oscillator
- GDYN 60.54
- ARQT 58.50
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc provides enterprise-level digital transformation in the areas of search, analytics, and release automation to Fortune 1000 companies. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.